Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillus anthracis spore inhalation challenge

The current study investigated the immunogenicity and protective response of rPA antigen formulated with the DPXTM no-release delivery platform (DPX-rPA). This unique formulation promotes a depot effect that attracts antigen-presenting cells to the vaccination site and elicits an immune response following single-dose delivery.

MSF begins enrolling patients in clinical trial of potential Ebola treatments

Doctors Without Borders/Médecins Sans Frontières (MSF) will participate in an ongoing randomized controlled trial of four potential Ebola treatments in North Kivu, Democratic Republic of Congo, in collaboration with the Ministry of Health, the international medical humanitarian organization said Tuesday.

Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus

Severe fever with thrombocytopenia virus is an emerging tick-borne arbovirus first reported in East and Central China in 2009, and subsequently in Korea and Japan. A closely related virus, termed Heartland virus, was identified and isolated from two patients in the US in 2012.